Cell systems and the toxic mechanism(s) of alpha-synuclein
- PMID: 17603039
- PMCID: PMC2231843
- DOI: 10.1016/j.expneurol.2007.05.022
Cell systems and the toxic mechanism(s) of alpha-synuclein
Abstract
Mutations in the SNCA gene are causal for familial Parkinson disease/Lewy body disease. alpha-Synuclein is a small acidic protein that binds loosely to the surface of vesicles and may play a role in synaptic dynamics, although its normal function remains somewhat unclear. What is clear is that point mutations or increased expression of wild type alpha-synuclein causes disease. A great deal of literature supports the overall hypothesis that alpha-synuclein is damaging to neurons because it is inherently prone to aggregation; mutations or increased concentration of the protein both increase this tendency. An unproven, but popular, contention is that the toxic species are small oligomers that are relatively soluble, which may react with membranes to damage key processes within the cell. The details of this process, especially in determining the order of events and the requirement of particular processes in cell death, are unclear. Derangements in vesicle processing, including synaptic function, protein turnover, mitochondrial function and oxidative stress, have all been suggested to occur. Whether there is a sequence of events or whether these are interacting effects is unclear, but the outcome is to trigger cell death, by both apoptotic and non-apoptotic mechanisms depending on the system studied. In this article, we develop a framework for thinking about alpha-synuclein in terms of initiating events and secondary processes that are required to trigger neuronal dysfunction and cell death.
Similar articles
-
Modulation of alpha-synuclein aggregation by dopamine: a review.Neurochem Res. 2009 Oct;34(10):1838-46. doi: 10.1007/s11064-009-9986-8. Epub 2009 May 15. Neurochem Res. 2009. PMID: 19444607 Review.
-
Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.Brain Res. 2000 Jun 2;866(1-2):33-43. doi: 10.1016/s0006-8993(00)02215-0. Brain Res. 2000. PMID: 10825478
-
The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.J Neurosci. 2000 Aug 15;20(16):6048-54. doi: 10.1523/JNEUROSCI.20-16-06048.2000. J Neurosci. 2000. PMID: 10934254 Free PMC article.
-
α-Synuclein and mitochondrial dysfunction in Parkinson's disease.Mol Neurobiol. 2013 Apr;47(2):587-97. doi: 10.1007/s12035-013-8394-x. Epub 2013 Jan 30. Mol Neurobiol. 2013. PMID: 23361255 Free PMC article. Review.
-
Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.Neuromolecular Med. 2003;4(1-2):21-36. doi: 10.1385/NMM:4:1-2:21. Neuromolecular Med. 2003. PMID: 14528050 Review.
Cited by
-
NSAIDs in the treatment and/or prevention of neurological disorders.Inflammopharmacology. 2012 Jun;20(3):159-67. doi: 10.1007/s10787-011-0116-2. Epub 2012 Jan 10. Inflammopharmacology. 2012. PMID: 22231719 Review.
-
Characterization of semisynthetic and naturally Nα-acetylated α-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of α-synuclein.J Biol Chem. 2012 Aug 17;287(34):28243-62. doi: 10.1074/jbc.M112.383711. Epub 2012 Jun 20. J Biol Chem. 2012. PMID: 22718772 Free PMC article.
-
Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences.EMBO J. 2012 Jun 26;31(14):3038-62. doi: 10.1038/emboj.2012.170. EMBO J. 2012. PMID: 22735187 Free PMC article. Review.
-
The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.EMBO J. 2008 Jan 23;27(2):336-49. doi: 10.1038/sj.emboj.7601930. EMBO J. 2008. PMID: 18216876 Free PMC article. Review.
-
Pros and cons of a prion-like pathogenesis in Parkinson's disease.BMC Neurol. 2011 Jun 20;11:74. doi: 10.1186/1471-2377-11-74. BMC Neurol. 2011. PMID: 21689433 Free PMC article.
References
-
- Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25:239–252. - PubMed
-
- Baptista MJ, O’Farrell C, Daya S, Ahmad R, Miller DW, Hardy J, Farrer MJ, Cookson MR. Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem. 2003;85:957–968. - PubMed
-
- Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001;292:1552–1555. - PubMed
-
- Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci. 2002;22:8797–8807. - PMC - PubMed
-
- Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, Galatis D, Sharples RA, Curtain CC, Ali FE, Cherny RA, Culvenor JG, Bottomley SP, Masters CL, Barnham KJ, Hill AF. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. Faseb J. 2005;19:1377–1379. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous